Literature DB >> 18949399

Overexpression of SENP5 in oral squamous cell carcinoma and its association with differentiation.

Xiaojun Ding1, Jian Sun, Lizhen Wang, Guolin Li, Yi Shen, Xiaojian Zhou, Wantao Chen.   

Abstract

Small ubiquitin-like modifiers (SUMOs) play an important role in tumors. The SUMOylation can be reversed by SUMO-specific proteases (SENPs). As one of the crucial members of the SUMO system, SENP5 is essential in mitosis and/or cytokinesis. In the present study, we analyzed the expression of SENP5 in human oral squamous cell carcinoma and investigated the relationship between its expression level and clinicopathological parameters. Expression levels of SENP5 in 48 patients with oral squamous cell carcinoma were investigated by immunohistochemistry. Immunoreactivity was evaluated semiquantitatively using German immunoreactive score (IRS). The relationship between SENP5 expression status and the clinical and pathological characteristics of patients was analyzed and survival curves were calculated using the Kaplan-Meier method and log-rank tests. We found that SENP5 predominantly localized to cytoplasm of OSCC cells and the expression of SENP5 in OSCC is not the same as in paracarcinoma epithelia. The SENP5 expression status was associated with differentiation of OSCC and not with any other clinicopathological parameters. These findings suggest altered subcellular localization of SENP5 in OSCC cells and the correlation between SENP5 expression and the differentiation of OSCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949399

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

Review 1.  Targeting nuclear thymidylate biosynthesis.

Authors:  James Chon; Patrick J Stover; Martha S Field
Journal:  Mol Aspects Med       Date:  2016-11-19

Review 2.  SUMO and the robustness of cancer.

Authors:  Jacob-Sebastian Seeler; Anne Dejean
Journal:  Nat Rev Cancer       Date:  2017-01-30       Impact factor: 60.716

3.  SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.

Authors:  Yan Han; Chao Huang; Xuxu Sun; Binggang Xiang; Ming Wang; Edward T H Yeh; Yuying Chen; Hui Li; Guiying Shi; Hui Cang; Yueping Sun; Jian Wang; Wei Wang; Fei Gao; Jing Yi
Journal:  J Biol Chem       Date:  2010-02-24       Impact factor: 5.157

Review 4.  SENP Proteases as Potential Targets for Cancer Therapy.

Authors:  Paulina Tokarz; Katarzyna Woźniak
Journal:  Cancers (Basel)       Date:  2021-04-24       Impact factor: 6.639

5.  Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells.

Authors:  Kun Wang; Xin-Chao Zhang
Journal:  Exp Ther Med       Date:  2014-03-28       Impact factor: 2.447

Review 6.  Advances in the development of SUMO specific protease (SENP) inhibitors.

Authors:  Ashutosh Kumar; Kam Y J Zhang
Journal:  Comput Struct Biotechnol J       Date:  2015-03-24       Impact factor: 7.271

7.  DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes.

Authors:  Susannah La-Touche; Christophe Lemetre; Maryou Lambros; Elzbieta Stankiewicz; Charlotte K Y Ng; Britta Weigelt; Ramzi Rajab; Brendan Tinwell; Cathy Corbishley; Nick Watkin; Dan Berney; Jorge S Reis-Filho
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

Review 8.  Current Status of SUMOylation Inhibitors.

Authors:  Christopher M Brackett; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

9.  Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation.

Authors:  Zujun Sun; Shuiqing Hu; Qingqiong Luo; Dongxia Ye; Dan Hu; Fuxiang Chen
Journal:  Oncol Rep       Date:  2013-03-01       Impact factor: 3.906

Review 10.  SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer.

Authors:  Karolin Eifler; Alfred C O Vertegaal
Journal:  Trends Biochem Sci       Date:  2015-10-22       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.